SENTI BIOSCIENCES, INC.

Analyst Reco. Senti Biosciences, Inc.

Equities

SNTI

US81726A1007

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
0.378 ^USD	+0.53%		+0.53%	-42.73%

May. 09	Senti Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 30	Senti Biosciences, Inc. Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Chardan Cuts Price Target on Senti Biosciences to $6 From $7, Keeps Buy Rating	23-05-11	MT
Morgan Stanley Adjusts Price Target on Senti Biosciences to $2 From $3, Keeps Equalweight Rating	23-03-24	MT
Chardan Adjusts Price Target on Senti Biosciences to $7 From $8, Keeps Buy Rating	23-03-23	MT
Chardan Adjusts Senti Biosciences' Price Target to $8 From $12, Keeps Buy Rating	23-01-30	MT
JPMorgan Initiates Coverage on Senti Biosciences With Neutral Rating	22-12-16	MT
Morgan Stanley Starts Senti Biosciences at Equalweight With $7.50 Price Target	22-10-07	MT
BofA Securities Starts Senti Biosciences at Buy With $7 Price Target	22-09-29	MT
Chardan Research Initiates Senti Biosciences With Buy Rating, $12 Price Target; Shares Climb 12% After Hours	22-09-22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW